Plasma high mobility group box 1 protein reflects fibrosis in pediatric nonalcoholic fatty liver disease-Reference-Cited by-同舟云学术

Plasma high mobility group box 1 protein reflects fibrosis in pediatric nonalcoholic fatty liver disease

Published:2014-06-13 Issue:6 Volume:14 Page:763-771
ISSN:1473-7159
Container-title:Expert Review of Molecular Diagnostics
language:en
Short-container-title:Expert Review of Molecular Diagnostics

Author:

Alisi Anna,Nobili Valerio,Ceccarelli Sara,Panera Nadia,De Stefanis Cristiano,De Vito Rita,Vitali Roberta,Bedogni Giorgio,Balsano Clara,Cucchiara Salvatore,Stronati Laura

Publisher

Informa UK Limited

Subject

Genetics,Molecular Biology,Molecular Medicine,Pathology and Forensic Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1586/14737159.2014.928205

Reference61 articles.

1. Epidemiology of Non-Alcoholic Fatty Liver Disease

2. A 360-degree overview of paediatric NAFLD: Recent insights

3. Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach

4. Is Nonalcoholic Fatty Liver Disease in Children the Same Disease as in Adults?

5. Relations of Steatosis Type, Grade, and Zonality to Histological Features in Pediatric Nonalcoholic Fatty Liver Disease

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oligonucleotide therapies for nonalcoholic steatohepatitis;Molecular Therapy - Nucleic Acids;2024-06

2. Pro- and anti-inflammatory cytokines are the game-changers in childhood obesity-associated metabolic disorders (diabetes and non-alcoholic fatty liver diseases);Reviews in Endocrine and Metabolic Disorders;2024-05-06

3. LXR Agonist T0901317′s Hepatic Impact Overrules Its Atheroprotective Action in Macrophages, Driving Early Atherogenesis in Chow-Diet-Fed Male Apolipoprotein E Knockout Mice;Biomolecules;2024-04-02

4. A patent review on HMGB1 inhibitors for the treatment of liver diseases;Expert Opinion on Therapeutic Patents;2024-03-03

5. Ubiquitination of cytoplasmic HMGB1 by RNF186 regulates hepatic lipophagy in non-alcoholic fatty liver disease;Metabolism;2024-03